DelveInsight's Persistent Corneal Edema Market Insights report includes a comprehensive understanding of current treatment ...
REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene ...
Alkeus’ presentation will be Wednesday, January 14, at 9:30 a.m. PST at The Westin St. Francis San Francisco, Mission Bay ...
Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials ...
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to ...
Company to highlight regulatory progress, clinical trial momentum, and multiple value-driving milestones expected in 2026DALLAS, /PRNewswire/ ...
A new approach to gene therapy for retinitis pigmentosa may help patients with advanced disease regain vision regardless of which genetic mutation is causing the condition. An optogenetic therapy ...
The FDA has accepted Opus Genetics' IND application for OPGx-BEST1, targeting BEST1-related inherited retinal disease. Best disease results from BEST1 gene mutations, causing macular degeneration and ...
Background/aims Inherited retinal dystrophies (IRD) are a group of predominantly monogenic disorders which have genetically heterogeneous origins and display wide clinical phenotypic heterogeneity.
In recent years, advances in molecular genetics have impacted the understanding and the classification of hereditary retinal and optic nerve disease perhaps more than any other group of eye diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback